Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Advertising (296)
- COVID-19 (160)
- Compliance and enforcement (106)
- Safety monitoring and information (100)
- Legislation (81)
- Vaping hub (59)
- Manufacturing (58)
- Import and export (42)
- Labelling and packaging (41)
- Medicinal cannabis hub (29)
- Scheduling (national classification system) (24)
- Sunscreens (20)
- Weight loss products (18)
- Peptide products (11)
- Shortages and supply disruptions (10)
- Committees and advisory bodies (8)
- Cosmetics (6)
- Clinical trials (5)
- Unique Device Identification (UDI) hub (5)
- Fees and payments (2)
- Prescription opioids hub (2)
- Urogynaecological (transvaginal) surgical mesh hub (2)
- Breast implant hub (1)
Search
1213 result(s) found, displaying 576 to 600
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
Media releasesThe transition period from the 2018 to the 2021 Advertising Code ends 30 June 2022.
-
Media releasesThe TGA has issued one infringement notice totalling $2,664 to a Queensland based individual for alleged unlawful advertising of therapeutic goods in relation to COVID-19.
-
Media releasesThe TGA has issued four infringement notices totalling $10,664 to an individual for alleged unlawful importation of COVID-19 rapid antigen tests (RATs).
-
Media releasesThe TGA has issued one infringement notice of $2,664 to a NSW based individual for the alleged unlawful advertising of a medicine that was not included in the Australian Register of Therapeutic Goods.
-
Media releasesThe TGA has issued ten infringement notices totalling $133,200 to Philips Electronics Australia Ltd.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
Media releasesThe TGA has issued 15 infringement notices totalling $39,960 to a New South Wales based individual for alleged unlawful importation of the prescription-only medicines ivermectin and doxycycline.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
Media releasesThe TGA has cancelled the listed complementary medicine FatBlaster Max (AUST L 348163) from the Australian Register of Therapeutic Goods (ARTG) for alleged breaches of the Therapeutic Goods Act 1989.
-
Media releasesTMF Cosmeceuticals Pty Ltd fined $26,640 for alleged unlawful importation of ivermectin
-
Media releasesThe TGA has issued one infringement notice of $2,664 to a Sydney based individual for alleged unlawful importation of unregistered anaesthetic products.
-
Media releasesThe TGA has issued three infringement notices totalling $39,960 to New South Wales based company Khazanah Nasional Pty Ltd for alleged unlawful advertising of disposable liquid nicotine vaping products.
-
Media releasesAussiewhip Pty Ltd fined $39,960 for alleged unlawful advertising of disposable nicotine vaping products
-
Media releasesThe TGA has determined that the BBIBP-CorV (Sinopharm) COVID-19 vaccine will be 'recognised' for all ages for the purpose of establishing a traveller's vaccination status when entering Australia.
-
Media releasesThe TGA has received and commenced evaluation of an application to extend the use of its COVID-19 vaccine, SPIKEVAX, to children aged 6 months to 5 years old.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
News articlesThe Prescribing Medicines in Pregnancy database has now been updated.
-
Media releasesFuturePro was convicted and released on recognisance, its directior was convicted and fined $25,000.
-
News articlesOn 10 July 2020 the Therapeutic Goods Administration (TGA) granted provisional approval to remdesivir ("Veklury", Gilead Sciences Pty Ltd) as the first treatment option for COVID-19
-
News articlesOn 20 August 2021 the TGA granted provisional approval to GlaxoSmithKline Australia Pty Ltd in relation to sotrovimab (XEVUDY).
-
Media releasesIndividual fined $2,664 for unlawful importation of nicotine vaping pods
-
Media releasesOn 7 April 2022, the TGA announced receipt of an application from GlaxoSmithKline (GSK) Australia Pty Ltd for a higher (1000 mg) dose of its COVID-19 treatment, XEVUDY (sotrovimab).